217 related articles for article (PubMed ID: 17062919)
1. Effects of valsartan and indapamide on plasma cytokines in essential hypertension.
Xie QY; Wang YJ; Sun ZL; Yang TL
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):629-34. PubMed ID: 17062919
[TBL] [Abstract][Full Text] [Related]
2. Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension.
Ke YS; Tao YY; Yang H; Yu GH
Acta Pharmacol Sin; 2003 Apr; 24(4):337-41. PubMed ID: 12676074
[TBL] [Abstract][Full Text] [Related]
3. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Fukuhara S; Iwasaka T
Thromb Res; 2006; 117(4):385-92. PubMed ID: 15896827
[TBL] [Abstract][Full Text] [Related]
4. Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial.
Hermida RC; Ayala DE; Khder Y; Calvo C
Clin Ther; 2008 Jan; 30(1):108-20. PubMed ID: 18343247
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of chemokines in acute myocardial infarction.
Kobusiak-Prokopowicz M; Orzeszko J; Mazur G; Mysiak A; Orda A; Mazurek W
Kardiol Pol; 2005 Apr; 62(4):301-14; discussion 315-6. PubMed ID: 15928736
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
[TBL] [Abstract][Full Text] [Related]
7. [Effect of valsartan on postprandial plasma inflammatory factors in patients with essential hypertension].
Liu L; Zhao SP; Zhou HN; Xu DY; Li JX
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 33(9):809-13. PubMed ID: 18812659
[TBL] [Abstract][Full Text] [Related]
8. [The relationship between the gene polymorphism of TGF-beta1 and early renal injury in patients with essential hypertension, and the effect of the gene polymorphism of TGF- beta1 on the individual treatment with valsartan].
Zhao C; Wang YY; Xiao ZX; Wang YP; Zhang QY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):428-31. PubMed ID: 17680535
[TBL] [Abstract][Full Text] [Related]
9. Valsartan reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension.
Li QZ; Deng Q; Li JQ; Yi GH; Zhao SP
Clin Chim Acta; 2005 May; 355(1-2):131-6. PubMed ID: 15820487
[TBL] [Abstract][Full Text] [Related]
10. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
11. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
[TBL] [Abstract][Full Text] [Related]
12. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension.
Rajagopalan S; Zannad F; Radauceanu A; Glazer R; Jia Y; Prescott MF; Kariisa M; Pitt B
Am J Cardiol; 2007 Jul; 100(2):222-6. PubMed ID: 17631074
[TBL] [Abstract][Full Text] [Related]
13. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients.
Munakata M; Nagasaki A; Nunokawa T; Sakuma T; Kato H; Yoshinaga K; Toyota T
Am J Hypertens; 2004 Nov; 17(11 Pt 1):1050-5. PubMed ID: 15533733
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
Calhoun DA; Glazer RD; Pettyjohn FS; Coenen PD; Zhao Y; Grosso A
Curr Med Res Opin; 2008 Aug; 24(8):2303-11. PubMed ID: 18593517
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients.
Fogari R; Derosa G; Zoppi A; Rinaldi A; Lazzari P; Fogari E; Mugellini A; Preti P
Hypertens Res; 2005 Mar; 28(3):209-14. PubMed ID: 16097363
[TBL] [Abstract][Full Text] [Related]
16. Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE.
Düsing R; Handrock R; Klebs S; Tousset E; Vrijens B
J Hypertens; 2009 Apr; 27(4):894-901. PubMed ID: 19300114
[TBL] [Abstract][Full Text] [Related]
17. Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients.
Yang HY; Kao PF; Chen TH; Tomlinson B; Ko WC; Chan P
J Clin Pharmacol; 2007 Mar; 47(3):397-403. PubMed ID: 17322151
[TBL] [Abstract][Full Text] [Related]
18. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men.
Fogari R; Preti P; Derosa G; Marasi G; Zoppi A; Rinaldi A; Mugellini A
Eur J Clin Pharmacol; 2002 Jun; 58(3):177-80. PubMed ID: 12107602
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension.
Kurata M; Okura T; Irita J; Enomoto D; Nagao T; Jotoku M; Miyoshi K; Desilva VR; Higaki J
J Hum Hypertens; 2011 May; 25(5):334-9. PubMed ID: 20664555
[TBL] [Abstract][Full Text] [Related]
20. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients.
Nakamura T; Fujii S; Hoshino J; Saito Y; Mizuno H; Saito Y; Kurabayashi M
Hypertens Res; 2005 Dec; 28(12):937-43. PubMed ID: 16671331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
